Abstract: Biocompatible matrices or implants on which one or more specific cell-interactive molecules (“biomolecules”) can be immobilized have been developed. The matrices allow for the independent control of ligand concentration and matrix strength. In one embodiment, the matrix or implant is modified with one or more moieties capable of complexing bioconjugates prepared from one or more biomolecules. Suitable moieties include phenyl boronic acid complexing agents, such as salicylhydroxamic acid, which can complex to one or more biomolecules containing one or more phenyl boronic acid moieties. The biomolecules may be anchored to the matrix via a spacer molecule, which may allow for greater mobility of the biomolecules in aqueous solution. In one embodiment, the matrix is a hydrogel material which has been doubly-derivatized, wherein ligand concentration and matrix strength can be independently controlled.

Abstract: Purified agarose suitable for rapid electrophoresis, characterized by a sulfate content of less than 0.2 wt % but greater than zero, a pyruvate content of 0-0.1 wt %, and a nitrogen content of 0-0.02 wt %. Gels prepared from the agarose exhibit a gel strength at 1.0 wt % concentration of at least 1200 g/cm.sup.2, substantial absence of DNA binding in 0.07 M or less tris acetate buffer, and an electroendosmosis (EEO) at 1.0 wt % concentration of 0.05 or less. Agaroses are purified to provide the low EEO material by dissolving agarose or alkali-modified agar in an aqueous medium buffered at a pH of 6.0 to 8.0 and containing no more than 2.0 nM salt as chloride, and precipitating the agarose by contact with a lower alkanol.